Three-year follow-up of the phase 3 TRANSFORM study of lisocabatagene maraleucel for second-line relapsed or refractory large B-cell lymphoma

The multinational phase 3 TRANSFORM study randomized patients with primary refractory or early relapsed (< 12 months) large B-cell lymphoma 1:1 to second-line lisocabtagene maraleucel (liso-cel) or standard of care (SOC). Three-year follow-up results of the study have now been published. Event-free survival, progression-free survival, and overall survival were better with liso-cel compared with SOC. Safety results were consistent with previous reports. The authors conclude that at 3-year follow-up, liso-cel confirmed superior, more durable efficacy versus SOC with a favorable safety profile.